Viridian Q3 Lumvoa Revenue Reaches $24.7 Million

Viridian Therapeutics (NASDAQ: VRDN) reported $24.7 million in net product revenue from Lumvoa in the third quarter of 2026, the thyroid eye disease therapy’s first quarter on the U.S. market. More than 100 patients were receiving the treatment as of September 30, giving the company an initial commercial base as it prepares for several pipeline milestones over the coming months.

Management said the Lumvoa launch exceeded its expectations, citing engagement with core prescribers, early patient demand and progress on market access. A permanent J-code has been assigned and will take effect on January 1, 2027, which should support standardized reimbursement as the launch continues.

Lumvoa launch remains the commercial focus

Viridian is concentrating its launch efforts on converting patient enrollments into infusions, encouraging broad and repeat prescribing, securing payer coverage and supporting physicians, patients and infusion centers through its ViridianCares patient-services program. The company identified approximately 2,000 core U.S. prescribers experienced with anti-IGF-1R infusions as its principal target group.

Lumvoa is an intravenous anti-IGF-1R therapy approved in the U.S. for thyroid eye disease. The company highlighted clinical improvements in proptosis and diplopia in both active and chronic disease, with proptosis reduction observed as early as three weeks in its studies. The treatment is administered over a 12-week regimen.

Viridian estimates the U.S. thyroid eye disease market at roughly $2 billion. The company said the market’s new-start treatment model could support uptake because each course of therapy represents a separate treatment decision, although continued growth will depend on payer access, physician adoption and patient initiation.

Elegrobart filing and pipeline milestones approach

Beyond Lumvoa, Viridian said it remains on track to submit a Biologics License Application for elegrobart in the first quarter of 2027. Elegrobart is a subcutaneous anti-IGF-1R candidate being developed for thyroid eye disease.

The company also expects to report Phase 1 data for VRDN-008, its bispecific extended-half-life FcRn inhibitor, in the fourth quarter of 2026. Viridian plans to provide broader development updates for its FcRn portfolio during the same period.

A Phase 1 trial of VRDN-292, a subcutaneous thyroid-stimulating hormone receptor inhibitor, is expected to begin in patients with Graves’ disease in the fourth quarter. The program remains at an earlier stage than the company’s thyroid eye disease assets.

Cash position supports current plans

Viridian reported $955 million in cash, cash equivalents and marketable securities. The company expects that balance, together with anticipated Lumvoa revenue and potential revenue from elegrobart if approved, will be sufficient to fund its current business plans through profitability.

That outlook remains dependent on commercial and clinical execution. Viridian has historically incurred losses and has limited experience generating product revenue. The presentation also identified potential risks involving Lumvoa market acceptance, manufacturing and commercial capabilities, payer access, competition, clinical-trial outcomes, regulatory timing and the company’s ability to obtain and maintain approvals. Delays or weaker-than-expected commercial revenue could also affect the sufficiency of its existing capital.